WO2007010398A3 - Caveolin-3 and in vitro culture of hepatitis c virus - Google Patents

Caveolin-3 and in vitro culture of hepatitis c virus Download PDF

Info

Publication number
WO2007010398A3
WO2007010398A3 PCT/IB2006/002565 IB2006002565W WO2007010398A3 WO 2007010398 A3 WO2007010398 A3 WO 2007010398A3 IB 2006002565 W IB2006002565 W IB 2006002565W WO 2007010398 A3 WO2007010398 A3 WO 2007010398A3
Authority
WO
WIPO (PCT)
Prior art keywords
caveolin
hcv
vitro culture
hepatitis
virus
Prior art date
Application number
PCT/IB2006/002565
Other languages
French (fr)
Other versions
WO2007010398A2 (en
Inventor
Marcello Merola
Stefania Crotta
Alessia Bianchi
Original Assignee
Novartis Vaccines & Diagnostic
Marcello Merola
Stefania Crotta
Alessia Bianchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Marcello Merola, Stefania Crotta, Alessia Bianchi filed Critical Novartis Vaccines & Diagnostic
Priority to EP06795507A priority Critical patent/EP1910522A2/en
Priority to CA002615558A priority patent/CA2615558A1/en
Priority to JP2008522095A priority patent/JP2009513109A/en
Publication of WO2007010398A2 publication Critical patent/WO2007010398A2/en
Publication of WO2007010398A3 publication Critical patent/WO2007010398A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Caveolin-3 has been identified as a cellular factor that associates with HCV protein El and E2, and is proposed as a cellular limiting factor. As an alternative possibility, caveolin-3 may act as a cellular receptor for HCV, acting alongside CD81. In either scenario, cells with increased expression of caveolin-3 will be better suited to the in vitro culture of HCV, and blocking the interaction between caveolin-3 and HCV proteins has therapeutic potential.
PCT/IB2006/002565 2005-07-18 2006-07-18 Caveolin-3 and in vitro culture of hepatitis c virus WO2007010398A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06795507A EP1910522A2 (en) 2005-07-18 2006-07-18 Caveolin-3 and in vitro culture of hepatitis c virus
CA002615558A CA2615558A1 (en) 2005-07-18 2006-07-18 Caveolin-3 and in vitro culture of hepatitis c virus
JP2008522095A JP2009513109A (en) 2005-07-18 2006-07-18 In vitro culture of caveolin-3 and hepatitis C virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70046205P 2005-07-18 2005-07-18
US60/700,462 2005-07-18

Publications (2)

Publication Number Publication Date
WO2007010398A2 WO2007010398A2 (en) 2007-01-25
WO2007010398A3 true WO2007010398A3 (en) 2007-04-19

Family

ID=37547530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002565 WO2007010398A2 (en) 2005-07-18 2006-07-18 Caveolin-3 and in vitro culture of hepatitis c virus

Country Status (4)

Country Link
EP (1) EP1910522A2 (en)
JP (1) JP2009513109A (en)
CA (1) CA2615558A1 (en)
WO (1) WO2007010398A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100984735B1 (en) * 2009-05-28 2010-10-01 동국대학교 산학협력단 New concept drug developement for screening drug candidate inhibitor of target protein-protein interaction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044182A2 (en) * 2002-11-13 2004-05-27 Washington University Highly permissive cell lines for hepatitis c virus replication
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044182A2 (en) * 2002-11-13 2004-05-27 Washington University Highly permissive cell lines for hepatitis c virus replication
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLIGHT K J ET AL: "Highly Permissive Cell Line for Subgenomic and Genomic Heptatis C VIrus RNA Replication", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 24, December 2002 (2002-12-01), pages 13001 - 13014, XP002984512, ISSN: 0022-538X *
BRAZZOLI MICHELA ET AL: "Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line.", JOURNAL OF HEPATOLOGY JAN 2007, vol. 46, no. 1, January 2007 (2007-01-01), pages 53 - 59, XP002418005, ISSN: 0168-8278 *
PIETSCHMANN T ET AL: "Persistent and transient replication of full-length hepatitis C virus genomes in cell culture", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 8, April 2002 (2002-04-01), pages 4008 - 4021, XP002377301, ISSN: 0022-538X *
SMART E J ET AL: "Caveolins, liquid-ordered domains, and signal transduction", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 19, no. 11, November 1999 (1999-11-01), pages 7289 - 7304, XP002212531, ISSN: 0270-7306 *
SONG KENNETH S ET AL: "Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells: Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 25, 1996, pages 15160 - 15165, XP002418004, ISSN: 0021-9258 *
TANG ZHAOLAN ET AL: "Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 4, 1996, pages 2255 - 2261, XP002418003, ISSN: 0021-9258 *
ZHONG JIN ET AL: "Robust hepatitis C virus infection in vitro", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 26, June 2005 (2005-06-01), pages 9294 - 9299, XP002418002, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2007010398A2 (en) 2007-01-25
JP2009513109A (en) 2009-04-02
CA2615558A1 (en) 2007-01-25
EP1910522A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
MY150685A (en) Molecules for blocking the infections by flaviviruses
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
ATE474827T1 (en) HCV REPLICATION INHIBITORS
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2007008657A3 (en) Hepatitis c virus inhibitors
TW200602078A (en) Uses of anti-CTLA-4 antibodies
WO2007136892A3 (en) Engineered antibody-stress protein fusions
GB0718984D0 (en) Structure of the hepatitis C virus NS5A protein
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2007053188A3 (en) Production of multivalent virus like particles
NZ593926A (en) Methods and compositions based on shiga toxin type 2 protein
AR069860A1 (en) METHOD FOR PURIFYING A CD20 ANTIBODY
ATE497392T1 (en) THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION
WO2010047830A3 (en) Agents for hcv treatment
WO2005081873A9 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
AR026059A1 (en) VIRUS OF MODIFIED PLANTS AND METHODS FOR USE
WO2018120843A9 (en) Trifunctional molecule and application thereof
MY141459A (en) Recombinant anti-idiotypic antibodies
EP2600894A4 (en) Modified hepatitis c virus proteins
EP1896588A4 (en) NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2615558

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008522095

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006795507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006795507

Country of ref document: EP